QC
MAZE

Quadrature Capital’s Maze Therapeutics MAZE Stock Holding History

Quadrature Capital’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$897K Buy
+30,047
New +$788K 0.01% 777

Other funds holding MAZE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
MGB
Mass General Brigham Somerville, Massachusetts $361M AUM
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Quadrature Capital's MAZE Position: Q2 2026 in Review

Quadrature Capital opened a new position in Maze Therapeutics (MAZE) in Q2 2026: 30,047 shares worth $897K. The stake represents 0.01% of the portfolio and ranks #777 among its holdings.

39 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Quadrature Capital held 30,047 shares of Maze Therapeutics worth $897K as of Q2 2026.
  • Maze Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Maze Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #777 holding.
  • 39 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.